NEWS & INSIGHTS /

Cure51 wants to sequence the DNA of survivors

Inside Cure51

Publication Date:
TO READ NEXT

"Nicolas Wolikow, co-founder and president of Cure 51, was Laure Closier's guest on French Tech on Friday, March 14. He explained his company's work with cancer survivors on Good Morning Business. "

Watch the video

Table of Contents
MORE ARTICLES IN THIS TOPIC
RELATED ARTICLES
yann-bizien-chloe-abadachi-cancer

Yann Bizien: 9 Years After a Stage IV Pancreatic Cancer Diagnosis

yann-bizien-chloe-abadachi-cancer

Yann Bizien: 9 Years After a Stage IV Pancreatic Cancer Diagnosis

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

until-all-survive-website-for-cancer-patients

UntilAllSurvive.com: we're launching a new website for cancer patients!

until-all-survive-website-for-cancer-patients

UntilAllSurvive.com: we're launching a new website for cancer patients!

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

READ MORE

MORE TOP STORIES
marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

CHUV-Centre-hospitalier-universitaire-vaudois

CHUV Lausanne received their Rosalind trophy!

precision-medicine-nicolas-wolikow

Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"

NEWS & INSIGHTS

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

We’re thrilled to announce a major milestone for Cure51: a strategic collaboration with Servier to uncover new therapeutic targets in glioblastoma

READ MORE

MORE TOP STORIES

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

Building a Product Ecosystem for Cancer Target Discovery

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

CHUV Lausanne received their Rosalind trophy!

CHUV-Centre-hospitalier-universitaire-vaudois

Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"

precision-medicine-nicolas-wolikow

How Cure51 Builds a Global Cancer Research Project Across 50+ Countries

Global-Cancer-Research-Compliance

NEWS & INSIGHTS

UNTIL ALL SURVIVE.

From frontline caregivers and patients to researchers and media voices, we bring diverse perspectives together to advance cancer research. Let’s talk.

Contact us

UNTIL ALL SURVIVE.

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

©2024 Cure51, All Rights Reserved

©2026 Cure51, All Rights Reserved

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

Follow us

Linkedin

Facebook

Instagram

Contact us

Contact us

Follow us

Linkedin

Facebook

Instagram

Contact us

ROSALIND

Contact us